Coxsackievirus Group B IgM ELISA Kit

This kit employs the capture ELISA principle to detect Coxsackievirus Group B (CVB) IgM antibodies in human serum. Microplate wells are pre-coated with mouse anti-human IgM (μ chain) antibodies, which specifically bind to all IgM antibodies present in the specimen. Upon adding the serum sample, the immobilized anti-μ antibodies capture the IgM fraction, while unbound components—including specific IgG antibodies and other serum proteins—are removed through washing steps to minimize interference. In the subsequent step, horseradish peroxidase (HRP)-conjugated CVB antigens (CVB-Ag-HRP) are introduced. The captured CVB-IgM antibodies within the wells specifically bind to these conjugated antigens, forming a stable immunocomplex: anti-μ chain antibody – CVB-IgM – CVB-Ag-HRP. Excess unbound conjugates are washed away to ensure only specific complexes remain, enhancing assay specificity. The final stage involves adding TMB (3,3',5,5'-tetramethylbenzidine) substrate, which is catalyzed by the HRP enzyme in the immunocomplex to produce a blue color reaction. Adding stop solution terminates the enzymatic reaction, converting the blue product to yellow. The absorbance (A value) is then measured at 450 nm using a microplate reader. The intensity of the color directly correlates with the presence of CVB-IgM antibodies in the sample. By comparing the absorbance against a validated cut-off value, the assay qualitatively determines acute or recent CVB infection. This two-step capture method ensures high sensitivity and specificity, reducing cross-reactivity with other viral antibodies and providing a reliable tool for clinical diagnosis of CVB-related diseases such as viral myocarditis and aseptic meningitis.